The Effects of Pharmacist-Led Medication Therapy Management on Medication Adherence and Use of Non-Steroidal Anti-Inflammatory Drug in Patients with Pre-End Stage Renal Disease

References

• Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11. doi:10.1016/j.kisu.2021.11.003
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States; 2022. Available from: https://adr.usrds.org/2022. Accessed August 6, 2023.
   Google Scholar
• Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662–664. doi:10.1016/S0140-6736(19)32977-0
   PubMed Web of Science ®Google Scholar
• Schmidt IM, Hubner S, Nadal J, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German chronic kidney disease study. Clin Kidney J. 2019;12(5):663–672. doi:10.1093/ckj/sfz046
   PubMed Web of Science ®Google Scholar
• Tangkiatkumjai M, Walker DM, Praditpornsilpa K, Boardman H. Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study. Clin Exp Nephrol. 2017;21(3):504–512. doi:10.1007/s10157-016-1312-6
   PubMed Web of Science ®Google Scholar
• Tesfaye WH, McKercher C, Peterson GM, et al. Medication adherence, burden and health-related quality of life in adults with predialysis chronic kidney disease: a prospective cohort study. Int J Environ Res Public Health. 2020;17(1):371. doi:10.3390/ijerph17010371
   PubMed Web of Science ®Google Scholar
• Griffin BR, Wendt L, Vaughan-Sarrazin M, et al. Nephrotoxin exposure and acute kidney injury in adults. Clin J Am Soc Nephrol. 2023;18(2):163–172. doi:10.2215/CJN.0000000000000044
   PubMedGoogle Scholar
• Luyckx VA, Tuttle KR, Garcia-Garcia G, et al. Reducing major risk factors for chronic kidney disease. Kidney Int. 2017;7(2):71–87. doi:10.1016/j.kisu.2017.07.003
   Web of Science ®Google Scholar
• Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–1172. doi:10.1007/s00228-014-1734-6
   PubMed Web of Science ®Google Scholar
• Parvez MK, Rishi V. Herb-drug interactions and hepatotoxicity. Curr Drug Metab. 2019;20(4):275–282. doi:10.2174/1389200220666190325141422
   PubMed Web of Science ®Google Scholar
• Britza SM, Byard RW, Musgrave IF. Traditional Chinese medicine-associated nephrotoxicity and the importance of herbal interactions–An overview. Pharmacol Res Mod Chin Med. 2022;3:100099. doi:10.1016/j.prmcm.2022.100099
   Google Scholar
• Levin A, Stevens PE, Bilous RW, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
   Web of Science ®Google Scholar
• Macedo E, Bihorac A, Siew ED, et al. Quality of care after AKI development in the hospital: consensus from the 22nd Acute Disease Quality Initiative (ADQI) conference. Eur J Intern Med. 2020;80:45–53. doi:10.1016/j.ejim.2020.04.056
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090. doi:10.2337/dci22-0027
   PubMed Web of Science ®Google Scholar
• Shivaprasad S, Mateti UV, Shenoy P, Shastry CS, Dharmagadda S. Clinical pharmacists’ scope of knowledge for medication therapy management in chronic kidney disease patients. Pharm Educ. 2021;21(1):781–788. doi:10.46542/pe.2021.211.781788
   Web of Science ®Google Scholar
• Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of chronic kidney disease patients: a systematic review. Int J Clin Pharm. 2019;41(3):630–666. doi:10.1007/s11096-019-00816-4
   PubMed Web of Science ®Google Scholar
• Khokhar A, Khan YH, Mallhi TH, et al. Effectiveness of pharmacist intervention model for chronic kidney disease patients; a prospective comparative study. Int J Clin Pharm. 2020;42(2):625–634. doi:10.1007/s11096-020-00982-w
   PubMed Web of Science ®Google Scholar
• Lin MY, Chang MY, Wu PY, et al. Multidisciplinary care program in pre-end-stage kidney disease from 2010 to 2018 in Taiwan. J Formos Med Assoc. 2022;121 Suppl 1:S64–S72. doi:10.1016/j.jfma.2021.12.008
   PubMed Web of Science ®Google Scholar
• Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118–123. doi:10.1111/j.1524-4733.2008.00400.x
   PubMed Web of Science ®Google Scholar
• Hayward S, Hole B, Denholm R, et al. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study. Nephrol Dial Transplant. 2021;36(3):503–511. doi:10.1093/ndt/gfaa064
   PubMed Web of Science ®Google Scholar
• Kimura H, Tanaka K, Saito H, et al. Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol. 2021;16(12):1797–1804. doi:10.2215/CJN.03940321
   PubMed Web of Science ®Google Scholar
• van Oosten MJ, Logtenberg SJ, Hemmelder MH, et al. Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. Clin Kidney J. 2021;14(12):2497–2523. doi:10.1093/ckj/sfab120
   PubMed Web of Science ®Google Scholar
• Seng JJB, Tan JY, Yeam CT, Htay H, Foo WYM. Factors affecting medication adherence among pre-dialysis chronic kidney disease patients: a systematic review and meta-analysis of literature. Int Urol Nephrol. 2020;52(5):903–916. doi:10.1007/s11255-020-02452-8
   PubMed Web of Science ®Google Scholar
• Santoro A, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Degli Esposti L. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. J Nephrol. 2022;35(2):463–472. doi:10.1007/s40620-021-01070-6
   PubMed Web of Science ®Google Scholar
• Cedillo-Couvert EA, Ricardo AC, Chen J, et al. Self-reported medication adherence and CKD progression. Kidney Int Rep. 2018;3(3):645–651. doi:10.1016/j.ekir.2018.01.007
   PubMed Web of Science ®Google Scholar
• Tesfaye WH, Erku D, Mekonnen A, et al. Medication non-adherence in chronic kidney disease: a mixed-methods review and synthesis using the theoretical domains framework and the behavioural change wheel. J Nephrol. 2021;34(4):1091–1125. doi:10.1007/s40620-020-00895-x
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Nuckols TK, Coles C, et al. A systematic overview of systematic reviews evaluating medication adherence interventions. Am J Health Syst Pharm. 2020;77(2):138–147. doi:10.1093/ajhp/zxz284
   PubMed Web of Science ®Google Scholar
• Mechta Nielsen T, Frojk Juhl M, Feldt-Rasmussen B, Thomsen T. Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research. Clin Kidney J. 2018;11(4):513–527. doi:10.1093/ckj/sfx140
   PubMed Web of Science ®Google Scholar
• Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256. doi:10.1186/s12882-017-0673-8
   PubMed Web of Science ®Google Scholar
• Jeon N, Park H, Segal R, Brumback B, Winterstein AG. Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients? Eur J Clin Pharmacol. 2021;77(9):1409–1417. doi:10.1007/s00228-021-03121-0
   PubMed Web of Science ®Google Scholar
• Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs. BMJ. 2001;323(7323):1236–1239. doi:10.1136/bmj.323.7323.1236
   PubMedGoogle Scholar
• Ljung R, Lu Y, Lagergren J. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging. 2011;28(6):469–476. doi:10.2165/11589070-000000000-00000
   PubMed Web of Science ®Google Scholar
• Pai AB. Keeping kidneys safe: the pharmacist’s role in NSAID avoidance in high-risk patients. J Am Pharm Assoc. 2015;55(1):e15–23; quiz e24–5. doi:10.1331/JAPhA.2015.15506
   Google Scholar
• Rashid R, Chang C, Niu F, et al. Evaluation of a pharmacist-managed nonsteroidal anti-inflammatory drugs deprescribing program in an integrated health care system. J Manag Care Spec Pharm. 2020;26(7):918–924. doi:10.18553/jmcp.2020.26.7.918
   PubMed Web of Science ®Google Scholar
• Cypes IN, Prohaska ES, Melton BL. Pharmacist impact on medication dosing and billable coding accuracy in outpatients with chronic kidney disease. J Am Pharm Assoc. 2021;61(2):e153–e158. doi:10.1016/j.japh.2020.10.009
   Google Scholar
• Schutze A, Hohmann C, Haubitz M, Radziwill R, Benohr P. Medicines optimization for patients with chronic kidney disease in the outpatient setting: the role of the clinical pharmacist. Int J Pharm Pract. 2021;29(6):587–597. doi:10.1093/ijpp/riab033
   PubMed Web of Science ®Google Scholar
• van Berlo-van de Laar IRF, Sluiter HE, Riet EV, Taxis K, Jansman FGA. Pharmacist-led medication reviews in pre-dialysis and dialysis patients. Res Social Adm Pharm. 2020;16(12):1718–1723. doi:10.1016/j.sapharm.2020.02.006
   PubMed Web of Science ®Google Scholar
• Roumeliotis N, Sniderman J, Adams-Webber T, et al. Effect of electronic prescribing strategies on medication error and harm in hospital: a systematic review and meta-analysis. J Gen Intern Med. 2019;34(10):2210–2223. doi:10.1007/s11606-019-05236-8
   PubMed Web of Science ®Google Scholar